Interim results of newly implemented clinical pharmacy services on an intern nephrology ward

被引:0
|
作者
Stemer, Gunar [1 ]
Lemmens-Gruber, Rosa [2 ]
机构
[1] Univ Clin, Vienna Gen Hosp, Dept Pharm, Vienna, Austria
[2] Univ Vienna, Dept Pharmacol & Toxicol, Vienna, Austria
来源
PHARMACY WORLD & SCIENCE | 2010年 / 32卷 / 02期
关键词
Nephrology; Clinical pharmacy; Drug-related problems;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:266 / 267
页数:2
相关论文
共 26 条
  • [21] A PHARMACOKINETICS CLINICAL STUDY OF BORTEZOMIB SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS INJECTION COMBINED WITH CHEMOTHERAPY IN CHINESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA-INTERIM RESULTS
    Fu, C.
    Wu, D.
    Zhu, X.
    Jin, S.
    Yan, L.
    Yan, S.
    Wang, P.
    Ge, Y.
    Chang, M.
    HAEMATOLOGICA, 2016, 101 : 794 - 794
  • [22] A multicentric randomized clinical trial comparing single vs double autologous peripheral blood stem cell transplantation for patients with newly diagnosed multiple myeloma: Results of an interim analysis.
    Tosi, P
    Cavo, M
    Zamagni, E
    Ronconi, S
    Benni, M
    Tura, S
    BLOOD, 1999, 94 (10) : 715A - 715A
  • [23] Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
    Munshi, Nikhil C.
    Lee, Saem
    Kambhampati, Suman
    Mohiuddin, Abid
    Rose, Michal
    Behler, Caroline
    Han, Andrew
    Efebera, Yvonne
    Houranieh, Antoun
    Brophy, Mary T.
    Zimelman, Abraham
    Prabhala, Rao H.
    Saba, Hussain I.
    Klein, Catherine
    Mehta, Paulette
    Hayes, Teresa
    Roodman, David
    Lichtenstein, Alan K.
    BLOOD, 2010, 116 (21) : 1262 - 1263
  • [24] Interim Results from a Phase I/II Clinical Gene Therapy Study for Newly Diagnosed Infants with X-Linked Severe Combined Immunodeficiency Using a Safety-Modified Lentiviral Vector and Targeted Reduced Exposure to Busulfan
    Mamcarz, Ewelina
    Zhou, Sheng
    Lockey, Timothy
    Abdelsamed, Hossam
    Cross, Shane
    Ma, Zhijun
    Dowdy, Jola
    Triplett, Brandon
    Weiss, Mitchell J.
    Ryu, Byoung Y.
    Dokmeci, Elif
    Aldave, Juan Carlos
    De Ravin, Suk See
    Youngblood, Benjamin
    Long-Boyle, Janel R.
    Meagher, Michael M.
    Malech, Harry L.
    Puck, Jennifer
    Cowan, Morton Jerome
    Sorrentino, Brian
    BLOOD, 2017, 130
  • [25] Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
    Sawalha, Yazeed
    Welkie, Rina Li
    Krivenko, Anna
    Hess, Brian
    Sigmund, Audrey M.
    Voorhees, Timothy
    Hanel, Walter
    Bond, David A.
    Reneau, John C.
    Epperla, Narendranath
    Alinari, Lapo
    Brammer, Jonathan E.
    Christian, Beth
    Baiocchi, Robert
    Maddocks, Kami J.
    BLOOD, 2023, 142
  • [26] Impact of Ph plus Stem Cell Burden on Clinical Findings and Molecular Responses to First-Line Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia: The Results from the Interim Analysis of N-Road, Multi-Center a Phase II Study
    Tsuda, Mayuko
    Nishiwaki, Kaichi
    Sugimoto, Kei-ji
    Yokoyama, Hisayuki
    Igarashi, Tadahiko
    Shimizu, Seiichi
    Yujiri, Toshiaki
    Wakita, Hisashi
    Tojo, Arinobu
    BLOOD, 2014, 124 (21)